Genocea Biosciences Company Description
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies.
The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens.
The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
The plan was later approved as Chapter 11 liquidation on May 11, 2023.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | William Clark |
Contact Details
Address: 100 Acorn Park Drive Cambridge, Delaware 02140 United States | |
| Phone | 617 876 8191 |
| Website | genocea.com |
Stock Details
| Ticker Symbol | GNCAQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| William D. Clark M.B.A. | President, Chief Executive Officer and Director |
| Diantha Duvall CPA, M.B.A. | Secretary |